

(19) 世界知的所有権機関
国際事務局(43) 国際公開日
2004年5月21日 (21.05.2004)

PCT

(10) 国際公開番号
WO 2004/041850 A1

(51) 国際特許分類⁷: C07K 7/08,
A61K 38/10, C07K 16/18, A61K 39/395

(21) 国際出願番号: PCT/JP2003/014138

(22) 国際出願日: 2003年11月6日 (06.11.2003)

(25) 国際出願の言語: 日本語

(26) 国際公開の言語: 日本語

(30) 優先権データ:
特願2002-324189 2002年11月7日 (07.11.2002) JP
特願2002-367119 2002年12月18日 (18.12.2002) JP
特願2003-59073 2003年3月5日 (05.03.2003) JP
特願2003-191359 2003年7月3日 (03.07.2003) JP

(71) 出願人(米国を除く全ての指定国について): 武田薬品工業株式会社 (TAKEDA CHEMICAL INDUSTRIES, LTD.) [JP/JP]; 〒541-0045 大阪府 大阪市中央区道修町四丁目1番1号 Osaka (JP).

(72) 発明者; および
(75) 発明者/出願人(米国についてのみ): 日沼司 (HINUMA,Shuji) [JP/JP]; 〒305-0821 茨城県つくば市春日1丁目7-9-1402 Ibaraki (JP). 小林真 (KOBAYASHI,Makoto) [JP/JP]; 〒651-2276 兵庫県神戸市西区春日台七丁目5-5 Hyogo (JP). 羽畠祐吾 (HABATA,Yugo) [JP/JP]; 〒305-0044 茨城県つくば市並木3丁目17-1-606 Ibaraki (JP). 原田征隆 (HARADA,Masataka) [JP/JP]; 〒305-0046 茨城県つくば市東2丁目14-5-201 Ibaraki (JP). 大久保尚一 (OKUBO,Shoichi) [JP/JP]; 〒300-1234 茨城県牛久市中央1丁目4-23 Ibaraki (JP). 吉田博美 (YOSHIDA,Hiromi) [JP/JP]; 〒300-2741 茨城県結城市石下町大字国生1444-23 Ibaraki (JP). 西一紀 (NISHI,Kazunori) [JP/JP]; 〒305-0044 茨城県つくば市並木4丁目16-1-402 Ibaraki (JP).

(74) 代理人: 高橋秀一, 外 (TAKAHASHI,Shuichi et al.); 〒532-0024 大阪府 大阪市淀川区十三本町2丁目17番8号 武田薬品工業株式会社大阪工場内 Osaka (JP).

(81) 指定国(国内): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) 指定国(広域): ARIPO 特許 (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), ヨーラシア特許 (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), ヨーロッパ特許 (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI 特許 (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

添付公開書類:
— 国際調査報告書

2文字コード及び他の略語については、定期発行される各PCTがゼットの巻頭に掲載されている「コードと略語のガイドノート」を参照。

WO 2004/041850 A1

(54) Title: NOVEL FPRL1 LIGANDS AND USE THEREOF

(54) 発明の名称: 新規なFPRL1リガンドおよびその用途

(57) Abstract: By using an FPRL1 ligand having an amino acid sequence which is the same or substantially the same as an amino acid sequence represented by SEQ ID NO:1, SEQ ID NO:17 or SEQ ID NO:21 together with FPRL1, an FPRL1 agonist or an FPRL1 antagonist can be efficiently screened.

(57) 要約: 配列番号: 1、配列番号: 17 または配列番号: 21 で表わされるアミノ酸配列と同一もしくは実質的に同一のアミノ酸配列を含有するFPRL1リガンドとFPRL1を用いることにより、FPRL1アゴニストまたはFPRL1アンタゴニストを効率良くスクリーニングすることができる。



INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP03/14138

A. CLASSIFICATION OF SUBJECT MATTER

Int.Cl' C07K7/08, A61K38/10, C07K16/18, A61K39/395

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Int.Cl' C07K7/08, A61K38/10, C07K16/18, A61K39/395

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Registry (STN), WPIDS/BIOSIS/BIOTECHABS/MEDLINE/CA (STN)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X A	ANDERSON S. et al., Sequence and organization of the human mitochondrial genome, Nature, 1981, Vol.290, pages 457 to 465	15 1-5, 10, 12-14, 17, 19, 20, 22-24, 26, 27, 59, 61
A	LE Y. et al., Formyl-peptide receptors revisited, Trends Immunol., 01 November, 2002 (01.11.02), Vol.23, pages 541 to 548	1-5, 10, 12-15, 17, 19, 20, 22-24, 26, 27, 59, 61

 Further documents are listed in the continuation of Box C. See patent family annex.

- * Special categories of cited documents:
- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "&" document member of the same patent family

Date of the actual completion of the international search
04 February, 2004 (04.02.04)Date of mailing of the international search report
17 February, 2004 (17.02.04)Name and mailing address of the ISA/
Japanese Patent Office

Authorized officer

Facsimile No.

Telephone No.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP03/14138

Box I Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: 58, 60
because they relate to subject matter not required to be searched by this Authority, namely:
These claims pertain to methods for treatment of the human body by surgery or therapy, as well as diagnostic methods.
2. Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

The peptides as set forth in claims 1 and 6 are common to each other not in chemical structure but exclusively in being an endogenous ligand of FPRL1. However, endogenous ligands of FPRL1 are publicly known as reported in document Int. Immunopharmacol., 2002, Vol. 2, p.1, etc. Therefore, this common matter is not regarded as a special technical feature within the meaning of the second sentence in PCT Rule 13.2. There is no other common matter between the peptides as claimed in claims 1 and 6 seemingly being a special technical feature within the meaning of the second sentence in PCT Rule 13.2. (Continued to extra sheet.)

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Claims 1 to 5, 10, 15, 17, 20, 24 and 27 and the parts depending on claims 1 to 5 in claims 12 to 14, 19, 22, 23, 26, 59 and 61.

Remark on Protest The additional search fees were accompanied by the applicant's protest.
 No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/JP03/14138

Continuation of Box No. II of continuation of first sheet(1)

The peptides as set forth in claims 1 and 29 are common to each other not in chemical structure but exclusively in being a peptide relating to FPRL1.

However, peptides relating to FPRL1 are publicly known as reported in document J. Biol. Chem., 1992, Vol.267, p.7637, document Int. Immunopharmacol., 2002, Vol.2, p.1, etc. Therefore, this common matter is not regarded as a special technical feature within the meaning of the second sentence in PCT Rule 13.2. There is no other common matter between the peptides as claimed in claims 1 and 29 seemingly being a special technical feature within the meaning of the second sentence in PCT Rule 13.2.

The same applies to claims 6 and 29.

Such being the case, the inventions as set forth in the present case are not considered as relating to a group of inventions so linked as to form a single general inventive concept. Thus it is recognized that there are 3 groups of inventions in the present case.

THIS PAGE BLANK (USPTO)